A Study of PF-04217903 in Patients With Advanced Cancer

Phase 1 Safety, Pharmacokinetic and Pharmacodynamic Study of PF-4217903 in Patients With Advanced Cancer

PF-04217903 may work in cancer by blocking the cell growth, migration and invasion of tumor cells. PF-04217903 is a new member in a class of drugs called c-Met/hepatocyte growth factor receptor tyrosine kinase inhibitors. This research study is the first time PF-04217903 will be given to patients. PF-04217903 is taken by mouth daily.

The study was prematurely discontinued due to a strategic development decision by Pfizer on 10FEB2012. The decision to terminate was not based on any safety concerns.

Inclusion Criteria:

• Advanced solid tumors, histologically proven at diagnosis which is refractory to standard of care or for whom no standard of care therapy is available
• Adequate blood cell counts, normal kidney function, and performance status of 0 or 1

Exclusion Criteria:

• Major surgery, radiation therapy or anti-cancer therapy within 2 weeks of starting study treatment
• Prior stem cell transplant
• Active or unstable cardiac disease or heart attack within 12 months of starting study treatment